-- Showed that its TRPm5-directed modulators can enhance the release of key hormones from intestinal chemosensory cells, including GLP1 which regulates glucose uptake and PYY, a hormone involved in satiety and appetite suppression.

-- Completed corporate restructurings in February and May of 2009 to reduce cash burn.

"During 2009 Redpoint made important advances in two related areas of taste biology, setting our course for a productive and exciting 2010. We were pleased to announce that our taste research platform led to the discovery of RP44, a novel, all-natural sweetness enhancer that has the potential to be used in making healthier food and beverage products. In addition, we leveraged our knowledge of taste signaling to work towards novel therapeutic approaches for diabetes and obesity, and have made exciting progress in this area," stated Ray Salemme, Ph.D., Chief Executive Officer of Redpoint. "These advances have greatly encouraged our team, particularly after we restructured early in 2009 to reduce our cash burn."

Dr. Salemme continued, "Our priorities for 2010 are to advance our all-natural sweetness enhancer, RP44, towards commercialization, and progressing our TRPm5 modulator program for the treatment of diabetes. We are actively seeking partners for these programs." Nonetheless, there can be no assurance that RP44 can be produced in large scale on an economically viable basis or that the Company will consummate collaborations with commercial partners.

Source Redpoint Bio Corporation